Form 4: Moderna's Chief Legal Officer Shannon Thyme Klinger Reports Stock Transactions

Chief Legal Officer of Moderna, Shannon Thyme Klinger, reports the acquisition and disposal of common stock and restricted stock units.

Summary

• On June 7, 2024, Shannon Thyme Klinger, Chief Legal Officer of Moderna, exercised restricted stock units (RSUs) converting into 1,139 shares of common stock.
• Also on June 7, 2024, Klinger exercised RSUs converting into 9,108 shares of common stock.
• On June 10, 2024, Klinger disposed of 5,178 shares of common stock at a price of $148.0851 per share to cover tax withholding obligations related to the vesting of RSUs.
• Following these transactions, Klinger directly owns 15,947 shares of Moderna common stock.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by an insider. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities. It doesn't necessarily reflect a broader trend in the pharmaceutical industry but is specific to the individual's financial planning and company policies.

Comparison to Industry Standards

• Form 4 filings are standard practice for corporate insiders across all publicly traded companies, including pharmaceutical giants like Pfizer, Johnson & Johnson, and Merck.
• The transactions reported are typical for executives who receive stock options or restricted stock units as part of their compensation packages.
• The 'sell to cover' mechanism for tax obligations is a common practice to manage tax liabilities associated with equity compensation.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the sale of shares, but the overall effect is likely minimal given the volume of shares traded daily.

Key Dates